“MGC Pharmaceuticals Ltd. said Monday that it has started the Phase 3 clinical trial for CimetrA.
The trial–taking place at Israel’s Rambam medical center–will evaluate the efficacy and safety of the Covid-19 treatment for hospitalized patients, it said.
The Australian biopharma company said the trial will also provide additional data for claims on the product as an investigational medicinal product. The first patient has already been recruited, MGC Pharmaceuticals added.”
